Orbimed Advisors LLC Neurocrine Biosciences Inc Transaction History

Orbimed Advisors LLC

$2.8 Billion
Q2 2025

A detailed history of Orbimed Advisors LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Orbimed Advisors LLC holds 438,540 shares of NBIX stock, worth $56.5 Million. This represents 1.97% of its overall portfolio holdings.

Number of Shares

438,540

Previous 934,640 53.08%

Holding current value

$56.5 Million

Previous $103 Million 46.68%

% of portfolio

1.97%

Previous 3.22%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$87.54 - $128.18 $43.4 Million - $63.6 Million	-496,100 Reduced 53.08%	438,540 $55.1 Million
Q1 2025 May 15, 2025	SELL	$107.22 - $153.29 $373,125 - $533,449	-3,480 Reduced 0.37%	934,640 $103 Million
Q4 2024 Feb 14, 2025	BUY	$111.62 - $139.44 $71 Million - $88.7 Million	635,900 Added 210.41%	938,120 $128 Million
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $16.7 Million - $22.4 Million	-145,980 Reduced 32.57%	302,220 $34.8 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $3.28 Million - $3.59 Million	25,100 Added 5.93%	448,200 $61.7 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $12.5 Million - $13.8 Million	-96,179 Reduced 18.52%	423,100 $58.4 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $11 Million - $13.7 Million	103,379 Added 24.86%	519,279 $68.4 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $6.87 Million - $8.56 Million	-73,100 Reduced 14.95%	415,900 $46.8 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $18.7 Million - $24.4 Million	-198,700 Reduced 28.89%	489,000 $49.5 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $22.3 Million - $26.5 Million	-208,845 Reduced 23.29%	687,700 $82.1 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $4.33 Million - $5.07 Million	47,000 Added 5.53%	896,545 $95.2 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $1.97 Million - $2.6 Million	-25,970 Reduced 2.97%	849,545 $82.8 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $4.09 Million - $5.35 Million	-56,400 Reduced 6.05%	875,515 $82.1 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $20.7 Million - $27.6 Million	-260,100 Reduced 21.82%	931,915 $79.4 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $3.37 Million - $3.87 Million	-39,100 Reduced 3.18%	1,192,015 $114 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $6.31 Million - $7.22 Million	-70,600 Reduced 5.42%	1,231,115 $120 Million
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $11.1 Million - $15.7 Million	115,800 Added 9.76%	1,301,715 $125 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $2.63 Million - $4.03 Million	30,900 Added 2.68%	1,185,915 $145 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $16.5 Million - $24.9 Million	219,045 Added 23.4%	1,155,015 $100 Million
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $55.5 Million - $75.8 Million	-639,200 Reduced 40.58%	935,970 $101 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $21.6 Million - $26.2 Million	-258,030 Reduced 14.08%	1,575,170 $142 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $92.8 Million - $123 Million	1,339,000 Added 270.94%	1,833,200 $162 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $24.3 Million - $44.3 Million	356,400 Added 258.64%	494,200 $35.3 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $4.73 Million - $6.66 Million	62,800 Added 83.73%	137,800 $13.5 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $5.69 Million - $6.93 Million	75,000 New	75,000 $6.22 Million
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $16.7 Million - $22.1 Million	-284,841 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $13.7 Million - $17.5 Million	284,841	284,841 $17.5 Million

Others Institutions Holding NBIX

# of Institutions

656

Shares Held

101M

Call Options Held

282K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.3B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.

Account

Orbimed Advisors LLC Neurocrine Biosciences Inc Transaction History